Are risk factors for stroke and coronary disease the same?

Current Opinion in Lipidology

Volumn 9, Issue 4, 1998, Pages 325-328

  Qizilbash, Nawab ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CHOLESTEROL; FIBRINOGEN; LIPID;

AGE; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; GENDER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; METHODOLOGY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SOCIAL CLASS; STROKE; TRANSIENT ISCHEMIC ATTACK;

CEREBROVASCULAR DISORDERS; CHOLESTEROL; CORONARY DISEASE; HUMANS; META-ANALYSIS; RISK FACTORS;

ANGINA;

EID: 0031711690     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199808000-00007     Document Type: Article

References (27)

1. Qizilbash N. The epidemiology of transient ischaemic attacks [D Phil thesis]. Oxford: University of Oxford; 1988.
2. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipids as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ 1991; 303:605-609.
3. Ockene IS, Miller NH. for the American Association Task Force on Risk Reduction. Cigarette smoking, cardiovascular disease and stroke. A statement for healthcare professional from the American Heart Association. Circulation 1997; 96:3243-3247.
4. Doll R, Peto R, Hall E, Wheatley K, Gray R. Mortality in relation to consumption of alcohol: 13 years of observations on male British doctors. BMJ 1994; 309:911-918.
5. Njolstad I, Lund-Larsen PG. Body height, cardiovascular risk factors, and risk of stroke in middle-aged men and women. A 14-year follow-up of the Finnmark Study. Circulation 1997; 94:2877-2882.
6. Gaziano JM, Hennekens CH, O'Donnell JC, Breslow JL, Buring JE. Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96:2520-2525. A hospital-based case control study of 340 cases of myocardial infarction and an equal number of controls matched for age, sex and community to examine fasting levels of various lipids. The study found that fasting triglycerides, as a marker of triglyceride-rich lipoproteins, may provide useful information about the thrombogenic potential of the lipoprotein profile, particularly for high-density lipoprotein cholesterol.
7. Corti MC, Barbato GM, Baggio G. Lipoprotein alterations and atherosclerosis in the elderly. Curr Opin Lipidol 1997; 8:236-241.
8. Prospective Studies Collaboration. Cholesterol, blood pressure and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653.
9. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen J. Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989; 320:904-910.
10. Qizilbash N, Duffy S, Warlow C, Mann J. Lipids are risk factors for ischaemic stroke: overview and review. Cerebrovasc Dis 1992; 2:127-136.
11. Dyker AG, Weir CJ, Lees KR. Influence of cholesterol on survival after stroke: retrospective study. BMJ 1997; 314:1584-1588.
12. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction. Circulation 1997; 96:1432-1437. A population-based, prospective, nested, case control study among 7983 ndividuals. This study evaluated the predictiveness of high resolution B-mode ultrasonography of the thickness of the intima-media of the common carotid artery for future stroke and myocardial infarction. Based on short-term follow-up, there was evidence that increased common carotid intima-media thickness was associated with future stroke and myocardial infarction.
13. Qizilbash N, Duffy S, Prentice C, Boothby M, Warlow C. Von Willebrand factor and risk of ischaemic stroke. Neurology 1997; 49:1552-1556.
14. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PTVM, et al. Tissue plasminogen activator and risk of myocardial infarction. Circulation 1997; 95:2623-2627.
15. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997; 28:1739-1743.
16. O'Donnell CJ, Ridker PM, Glinn RJ, Berger K, Ajani U, Manson JE, Hennekens CH. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation 1997; 95:1132-1137.
17. Easton DF, Peto J, Babiker A. Floating absolute risk: an alternative to relative risk in survival and case control analysis avoiding a reference group. Stat Med 1991; 10:1025-1035.
18. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256:2823-2828.
19. MacMahon SW, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part I, prolonged differences in blood pressure; prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
20. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308:367-372.
21. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne G, Harlan WR. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992; 2:161-176.
22. Benfante R, Yano K, Hwang L-J, Curb D, Kagan A, Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk. Stroke 1994; 25:814-820.
23. Gatchev O, Rastam L, Lindberg G, Gullberg B, Eklund G, Isacsson S-O. Subarachnoid haemorrhage, cerebral haemorrhage, and serum cholesterol in men and women. Ann Epidemiol 1993; 3:403-409.
24. Hebert PR, Gaziano JM, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomised trials. JAMA 1997; 278:313-321. A systematic review of the trials of cholesterol reduction with hydroxymethylglutaryl-coenzyme A reductase inhibitors examining stroke and total mortality A total of 16 trials were included, with 29 000 individuals treated for an average of 3.3 years with average reductions of total cholesterol of 22% 454 strokes occurred in the follow-up period and those assigned to the statin drugs experienced a significant reduction in future stroke of 29% (95% Cl: 14%-41%).
25. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomised controlled trials. Ann Intern Med 1998; 128:89-95. A systematic review of the trials of cholesterol reduction with hydroxymethylglutaryl-coenzyme A reductase inhibitors or other lipid lowering interventions, examining stroke and total mortality. A total of 28 trials were included with 106 113 individuals treated for 0.5 years to 10 years with reductions of total cholesterol ranging from 34%. The trials were very heterogeneous and only the statin group of trials produced significant reductions in stroke risk of 0.76 (95% Cl: 0.62-0.42), Trials of fibrates, resins and dietary interventions did not provide evidence of reduction in stroke.
26. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995; 155:50-55.
27. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB. Cholesterol reduction and the risk of stroke in men. Ann Intern Med 1993; 119:136-145.